Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring.

Drug Des Devel Ther · 2026 · PMC13285935 · PMID 42338759

Europe PMC DOI

hedged sentence

0.0870

closest p · 1.7× alpha

0.0870

boldest claim

The sentences

did not reach statistical significancep=0.087so close (0.05 < p ≤ 0.1)

90.81±43.67 ng/mL for <35 years), though these differences did not reach statistical significance (p=0.087).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.